Hyperthermic isolation limb perfusion (HILP) in the management of extremity melanoma and sarcoma with particular reference to the dosage, pharmacokinetics, and toxicity of cisplatin.
Fletcher
W S
WS
Woltering
E A
EA
Moseley
H S
HS
Bos
G
G
Lebredo
L
L
Brown
D
D
Small
K
K
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D005121:Extremities; D006801:Humans; D006979:Hyperthermia, Induced; D015994:Incidence; D008545:Melanoma / Q000188:drug therapy / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy / Q000628:therapy*; D012206:Rhabdomyolysis / Q000139:chemically induced; D012878:Skin Neoplasms / Q000188:drug therapy / Q000628:therapy*; D016896:Treatment Outcome
D003609:Dactinomycin; D003606:Dacarbazine; D002945:Cisplatin; D008558:Melphalan